The Oncology Institute, Inc.

How big is The Oncology Institute, Inc.?

As of Jun 18, The Oncology Institute, Inc. has a market capitalization of 215.08 million, with net sales of 403.16 million and a net profit of -52.80 million over the last four quarters. Shareholder's funds are reported at 3.59 million, and total assets amount to 181.91 million.

As of Jun 18, The Oncology Institute, Inc. has a market capitalization of 215.08 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 403.16 million, while the sum of net profit for the same period is -52.80 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 3.59 million, and total assets amount to 181.91 million.

What does The Oncology Institute, Inc. do?

The Oncology Institute, Inc. operates in the Pharmaceuticals & Biotechnology sector, focusing on healthcare-related business combinations, with recent net sales of $104 million and a net loss of $16 million. The company has a market cap of $215.08 million and key metrics indicating significant financial challenges.

Overview: <BR>The Oncology Institute, Inc. is a company in the Pharmaceuticals & Biotechnology industry, focusing on healthcare-related business combinations.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 104 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 215.08 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 8.08 <BR>Return on Equity: -1,040.97% <BR>Price to Book: 42.43<BR><BR>Contact Details: <BR>Address: 780 Third Avenue, NEW YORK NY: 10017 <BR>Tel: 1 212 5511600 <BR>Fax: 1 302 6365454

Should I buy, sell or hold The Oncology Institute, Inc.?

Is The Oncology Institute, Inc. overvalued or undervalued?

As of May 10, 2023, The Oncology Institute, Inc. has shifted from an attractive to a risky valuation grade due to severe inefficiencies reflected in its negative financial ratios, indicating it is overvalued despite a significant year-to-date stock return of 948.54%.

As of 10 May 2023, the valuation grade for The Oncology Institute, Inc. has moved from attractive to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, particularly given its significant negative ratios, including a Price to Book Value of 48.83 and an EV to EBITDA of -6.34. Additionally, its ROCE stands at a troubling -113.07%, reflecting severe inefficiencies in capital utilization.<BR><BR>In comparison to its peers, The Oncology Institute's EV to EBITDA ratio of -8.88 is considerably worse than Nutex Health, Inc., which has a very attractive EV to EBITDA of 1.88, highlighting a stark contrast in operational performance. Other risky peers like LifeMD, Inc. and The Joint Corp. also exhibit negative EV to EBITDA ratios, but none approach the extreme levels seen with The Oncology Institute. Despite a remarkable year-to-date stock return of 948.54%, which significantly outperformed the S&P 500's 12.22%, the long-term outlook remains concerning, especially given the negative returns over the past three and five years.

Is The Oncology Institute, Inc. technically bullish or bearish?

As of August 25, 2025, The Oncology Institute, Inc. shows a mildly bullish trend with strong year-to-date performance of 948.54%, despite mixed signals from technical indicators and underperformance over the past 3- and 5-year periods.

As of 25 August 2025, the technical trend for The Oncology Institute, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating mild bullishness, while the weekly MACD and KST show mildly bearish signals. The monthly MACD and KST are bullish, and Bollinger Bands reflect a bullish to mildly bullish trend across time frames. However, the weekly RSI shows no signal and the monthly RSI is bearish, indicating some weakness.<BR><BR>In terms of performance, the company has significantly outperformed the S&P 500 year-to-date with a return of 948.54% compared to the S&P 500's 12.22%, but it has underperformed over the longer 3-year and 5-year periods.